Spencer Pharmaceutical and National Pharmaceutical have signed a preliminary agreement to develop central nervous disease treatments.

Under the agreement, the two companies will develop central nervous disease treatments for Alzheimer’s and Parkinson’s disease using the drug-delivery platform developed by Spencer.

The preliminary agreement requires a share swap of 20 million restricted shares, while the final terms and conditions of the transactions will be finalised in a definitive agreement.